The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: RBS Plummets As Dividend Lags Consensus

Fri, 14th Feb 2020 10:41

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.

----------

FTSE 100 - WINNERS

----------

SEGRO, up 0.7%. 2019 was another year of "strong" financial and operational performance for SEGRO, it said, supported by rental growth and additional income generated from its development pipeline. The real estate investment trust upped its dividend payment for the year and added that it has made a strong start to 2020 due to continuation of the earnings momentum. For 2019, SEGRO recorded pretax profit of GBP902.0 million, down 18% from GBP1.09 billion in 2018, mainly due to lower realised and unrealised gains in its wholly-owned portfolio. Adjusted pretax profit, however, jumped 11% to GBPP267.5 million from GBP241.5 million due to a record year of development completions, high customer retention rates, like-for-like rental growth and a low vacancy rate. SEGRO raised its final payout for 2019 by 8.7% to 14.4p, giving a total payout of 20.7p, up 10%.

----------

FTSE 100 - LOSERS

----------

Royal Bank of Scotland Group, down 6.2%. RBS saw profit and net interest income beat expectations in 2019, but declared a final ordinary dividend of 3p, down 32% or 1.4p, versus consensus expectations. The bank is also paying a 5p special dividend, taking its total 2019 distribution to 22.0p. The lender intends to maintain dividends around 40% of attributable profit, while consensus stands at 42%. RBS said it expects 2020 to "challenge" its ability to generate income, with its own economic forecasts predicting a base rate cut in the short term. In 2019, the state-backed lender's operating pretax profit increased 26% to GBP4.23 billion from GBP3.36 billion in 2018. Operating pretax profit, according to company-compiled consensus, was forecast at GBP3.77 billion. The bank's attributable profit for 2019 came in at GBP3.13 billion, compared to consensus of GBP2.52 billion. In 2018, when RBS reported its second profit in a decade, the figure was GBP1.62 billion. Total income was GBP14.25 billion, compared to 2018's GBP13.40 billion and the market expectation of GBP13.66 billion.

----------

FTSE 250 - WINNERS

----------

Pennon Group, up 0.5%. The water utility and waste management firm's South West Water business has accepted water regulator Ofwat's final determination for the period from 2020 to 2025. Pennon confirmed it will not refer the decision to the UK Competition & Market Authority. "Importantly for customers, by 2025 South West Water bills will be lower than they are today and lower than they were 15 years earlier," Pennon added. In December, Ofwat completed its price review for the period from 2020 to 2025, unveiling a GBP51 billion investment programme by UK utilities for the improvement of services and the environment.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Active Energy, up 23%. The London-based renewable energy company has agreed with all of its bondholders to revise the terms and conditions of its 2022 outstanding convertible bond. The convertible bond was issued in 2017 with a maturity date of mid-March 2022 and an interest coupon of 8% per annum, payable quarterly in arrears. All of the bondholders have now agreed that payment of these cash coupon payments will not be required for the 12-month period to the end of September. This will allow the company to focus its capital on current activities at its Lumberton site in North Carolina, it said.

----------

Verona Pharma, up 3.2%. The clinical-stage biopharmaceutical company reported phase 2b clinical trial results for ensifentrine as a maintenance treatment for chronic obstructive pulmonary

disease. The study met its primary endpoint demonstrating that ensifentrine produced clinically and statistically significant improvements in lung function at all doses. Also, clinically relevant secondary endpoints were met including significant progressive improvements in chronic obstructive pulmonary disease symptoms.

----------

SDX Energy, up 2.9%. The Mediterranean and North Africa-focused oil and gas company said drilling at the SD-6X well at the South Disouq project in Egypt has commenced. SDX has a 55% working interest in South Disouq, which is on the country's northern coast. The well, also known as Salah, is to be drilled to around 9,000 feet by late March or early April. It is targeted a resource of around 71 billion cubic feet equivalent of gas. The main targets of the well are in the same formations as London-based SDX's four producing wells, Kafr el Sheikh and Abu Madi. If the wells are successful, SDX said they would require tie-ins to the South Disouq central processing facility, which would cost SDX USD4.4 million combined.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Mosman Oil & Gas, down 40%. The exploration company said it has been considering its corporate strategy and priorities, particularly given the "success" at the Stanley project in Texas, US. In order to capture the growth opportunity, the company said it has established a funding plan, which includes an equity placing and non-core assets sale. Thus, Mosman said it will sell its Welch and Arkoma projects and launch a GBP300,000 fundraising. Mosman intends to issue 200.0 million shares at a price of 0.15 pence each. The proceeds will be used for the near term drilling programme at Stanley, the company said and expansion into new projects in Texas. Turning to production, the company reported a 13% increase in net output to 54,987 barrels of oil equivalent.

----------

Ascent Resources, down 37%. The oil & gas exploration and production company proposed a corporate restructuring, with James Parsons joining the company as executive chair. He is currently executive chair of Regency Mines and non-executive chair of Echo Energy and Coro Energy. Ascent said its shares are currently trading at below nominal value, which does not allow it to issue any further shares. The company, therefore, proposed a capital reorganisation, whereby each existing ordinary share of 0.2p nominal value is subdivided into one redenominated ordinary share of 0.005p and a deferred share of 0.195p, and a consolidation of the redenominated shares by a factor of 100 to 1. Upon completion, the company said it plans to propose a fundraising to raise GBP800,000 through a 16.0 million shares placing at a price of 5 pence each.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
7 Mar 2014 09:39

Friday broker round-up UPDATE

AGA Rangemaster: N+1 Singer ups target price from 175p to 192p and maintains a buy recommendation. Aggreko: JP Morgan lowers target price from 1542p to 1536p and maintains a neutral rating. Goldman Sachs increases target price from 1876p to 1950p and keeps a buy recommendation. Numis upgrades to re

Read more
6 Mar 2014 18:02

Verona Pharma Looks To Raise Up To GBP14 Million In Share Placing

LONDON (Alliance News) - Verona Pharma PLC Thursday said it intends to raise up to GBP14 million before expenses in a share placing, subscription, and open offer, which it said it will use to fund further development of its RPL554 drug. The drug development company focuses on medicines to t

Read more
11 Nov 2013 08:50

Monday broker round-up UPDATE

Associated British Foods: Barclays downgrades to equal-weight with a target price of 2100p. Bovis Homes Group: Deutsche Bank moves target price from 1001p to 1008p maintaining a buy recommendation. British Land: Deutsche Bank downgrades to sell with a target price of 520p. British Sky Broadcastin

Read more
25 Oct 2013 08:35

Verona Pharma Says RPL554 Drug Trial Positive

Read more
30 Sep 2013 12:47

Verona Pharma Widens Losses As Treatment Development Continues

Read more
5 Sep 2013 09:37

Verona Pharma Appoints Chroma CEO Bungay As New Part-Time CFO

Read more
5 Sep 2013 08:15

Verona Pharma replaces CFO Lowe with Bungay

Verona Pharma on Thursday said Chief Financial Officer (CFO) Danny Lowe would be replaced by Richard Bungay with immediate effect. Bungay will work part-time at the respiratory treatments specialist at first and Lowe will work with him for an interim period to make sure there is a smooth handover.

Read more
23 Jul 2013 16:21

SABMilller Chairman sells over 11m pounds in shares

Graham Mackay, the Chairman of SABMiller who is currently on a medical leave of absence due to a brain tumour, has sold over 11m pounds-worth of shares in the company. Mackay sold a total of 350,000 shares between July 16-18th through three separate transactions, the firm revealed on Tuesday. He so

Read more
26 Apr 2013 15:09

Advanced Oncotherapy CEO makes triple purchase

The Chief Executive of Advanced Oncotherapy, a provider of new technology for innovative and patient-focused cancer treatments, has this week purchased three lots of shares in the group, taking his stake to just under 69.4m shares. On Thursday Sinclair purchased one round of 8.075m shares at 1.59p

Read more
10 Apr 2013 16:27

AZ Electronic Materials directors try to minimize damage

John Whybrow, the Chairman of AZ Electronic Materials, which on Tuesday tanked after it issued a warning on full year revenue, has shown his faith in the chemicals company by enlarging his shareholding. Whybrow acquired 40,000 shares at 254p each for a total trade value of £101,600, taking his sta

Read more
4 Sep 2012 08:58

Small caps round-up: Verona, Image Scan, Avia

Respiratory diseases specialist Verona Pharma has hailed a positive outcome of a clinical trial of its lead drug candidate, the snappily-named RPL554. The data showed that a single dose of RPL554 in spray form administered to patients with chronic obstructive pulmonary disease (COPD) produced a ra

Read more
28 Aug 2012 14:43

Small caps round-up: Transense Tech, Hightex, Verona Pharma

Transense Technologies, which provides sensor systems for the transportation and industrial markets, has reported that its trading division, Translogik, has received an initial order for its iTrack Tyre Temperature and Pressure Monitoring Systems for mining and off-the-road vehicles from its Indones

Read more
9 Jul 2012 10:25

Small caps round-up: Lighthouse, Verona Pharma, Manroy...

Shares in Lighthouse Group, the financial advice and wealth management group, plunged on Monday after the company proposed to cancel its listing on AIM. The group must receive approval from shareholders representing at least three-quarters of the company's shares for the cancellation to be approved.

Read more
26 Nov 2010 15:56

Small caps round-up: Verona Pharma, PHSC, Sterling Green

Verona Pharma, respiratory diseases treatment developer, is initiating a new higher dose trial of its lead drug, RPL554, in patients with asthma, after receiving the go-ahead from the Dutch authorities. The company also announced that it has completed proof of concept trials on delivering RPL554 vi

Read more
28 Jun 2010 07:33

Verona Pharma In Talks With Licensees For RPL554 Cough Project

LONDON (Dow Jones)--Verona Pharma PLC (VRP.LN), an AIM quoted drug discovery company, said Monday licensing discussions continue to advance with potential licensees for its RPL554 cough project and it plans three clinical trials to add value to licensing package for RPL554. MAIN FACTS: -Has

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.